Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Case 1: Heavily Treatment–Experienced Patient—Part 1

In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.
Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD
Daniel R. Kuritzkes, MD
Released: October 29, 2021

This program is divided into several short segments that you can step through using the Video Chapters menu.
PreviousNext

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief,
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty

Rajesh T. Gandhi, MD

Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.
Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO) slideset providing expert insights for ART management in complex clinical situations, including extensive previous treatment

Released: July 1, 2022

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings